Edition:
India

Ipsen SA (IPN.PA)

IPN.PA on Paris Stock Exchange

111.20EUR
20 May 2019
Change (% chg)

€2.10 (+1.92%)
Prev Close
€109.10
Open
€110.10
Day's High
€111.70
Day's Low
€109.60
Volume
17,947
Avg. Vol
117,096
52-wk High
€155.95
52-wk Low
€98.85

Select another date:

Mon, Feb 25 2019

Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 billion

PARIS French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion, the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases.

Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 billion

PARIS French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion, the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases.

UPDATE 2-Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 bln

* Takeover worth up to $1.31 billion (Adds share price reaction and analyst comment)

RPT-Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 bln

PARIS, Feb 25 French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion, the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases.

Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 bln

PARIS, Feb 25 French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion, the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases.

Select another date: